All In Biotech

Drug Trial Radar · NCT06767800

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Chemotherapy With Behmosubstituted Monoclonalb/Pembrolizumab ± Chemotherapy in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Sep 2026

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction 2 (ECD2) and Endothelial Cell Dysfunction 4 (ECD4), increasing HER2 internalization, and then down-regulating the tumor cell surface HER2 proteins more effectively, and doubly blocking the HER2 signaling, to achieve the effects of trastuzumab and Pertuzumab alone and in combination. This is a Phase II study to evaluate the efficacy and safety of TQB2102 for injection in combination with Benmelstobart Injection /Penpulimab Injection ± chemotherapy in patients with unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma

Conditions

  • Gastroesophageal Adenocarcinoma

Interventions

  • TQB2102 for injection (7.5 mg) +Benmelstobart+ChemotherapyDrug

    TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody

  • TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+ChemotherapyDrug

    TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody

  • TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+ChemotherapyDrug

    TQB2102 for injection is an antibody-coupled drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Through study completion, an average of 1 year

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Fuyang Cancer Hospital

    Fuyang, Anhui, China · Not yet recruiting

  • Lu'an People's Hospital

    Lu'an, Anhui, China · Not yet recruiting

  • Maanshan People's Hospital

    Maanshan, Anhui, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The first affiliated hospital of chongqing medical university

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Gansu Prouincial Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China · Not yet recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Guilin Medical College

    Guilin, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The first affiliated hospital of hainan medical university

    Haikou, Hainan, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Tangshan People's Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Anyang Cancer Hospital

    Anyang, Henan, China · Not yet recruiting

  • The 1st Affiliated Hospital of He'nan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • Puyang Oilfield General Hospital

    Puyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital Of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • NanJing Drum Tower Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangning Hospital of Nanjing City

    Nanjing, Jiangsu, China · Not yet recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

  • Fudan university shanghai cancer center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi Cancer hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Nanchong Central Hospital

    Nanchong, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Xinjiang Medical University Affiliated Cancer Hospital

    Ürümqi, Xinjiang, China · Not yet recruiting

  • Wenzhou Medical University Affiliated First Hospital

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.